PhRMA Wades In Over Colombian Hep C Declaration Of Public Interest
Executive Summary
Declaring hepatitis C drugs to be of public interest would establish a dangerous precedent, PhRMA, the US pharma industry association has warned the Colombian health ministry.
You may also be interested in...
Colombia Celebrates Massive Hep C Price Fall Thanks to Joint Procurement
Colombian authorities have welcomed savings of 90% for hepatitis C treatments thanks to a pooled procurement initiative supported by the Pan American Health Organization.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.